GENENTECH, INC for GENENTECH INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2011 | $1,248,359 | Replaced |
| 1st Quarter - Amendment (this page) | Sep 21, 2012 | $1,258,359 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Food Industry (safety, labeling, etc.) FOO
Monitor and report and food safety and supply chain issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
Trade (domestic/foreign) TRD
Monitor issues related to export rules and regulations, international patent issues; matters and other international issues impacting biotech and pharmaceuticals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| KATHERINE RAAB | Director |
Taxation/Internal Revenue Code TAX
General tax issues and tax extenders; Monitoring proposals on U.S. tax treatment of foreign corporations;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| ELI KOGAN | Assoc. Director |
| EVAN MORRIS | VP |
Health Issues HCR
Avastin, Lucentis, FDA, Appropriations; Issues concerning clinical trias. General health care reform (Patient Protection and Affordable Care Act). Congressional oversight issues; Legislation on public health preparedness and response to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels; FDA approval and enforcement issues; Prescription Drug User Fee Act (PDUFA), Avastin - use in breast cancer treatment, macular degeneration, S.726/HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act; HR 1548 - Pathway for Biosimilars Act, General support for Genentech products; HR1/1473 health care funding : FY 12 Labor HHS Appropriations legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| ELI KOGAN | Assoc. Director |
| EVAN MORRIS | VP |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Implementation of HR 1: Medicare Prescription Drug and Modernization Act of 2003, Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness an CMS converge of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines; Monitor implementation of Medicare pharmaceutical converge and reimbursement provisions of PL 111-148 - Patient Protection and Affordable Care Act and PL 111-152 Health Care and Education Reconciliation Act; Advocacy related to ensuring access to necessary medicines; PHA Advocacy related to ensuring access to necessary medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| ANNA GRIFFIN | Director |
| EVAN MORRIS | VP |
Budget/Appropriations BUD
Issues related to pandemic preparedness and macular degeneration; FY11, FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment. Implementation of HR 2346, S.1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| EVAN MORRIS | VP |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.